Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ACTAVIS
EQUITY SHARE DATA
    CIPLA
Mar-23
ACTAVIS
Dec-18
CIPLA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,18516,159-   
Low Rs85210,840-   
Sales per share (Unadj.) Rs281.93,963.8-  
Earnings per share (Unadj.) Rs35.1-1,276.8-  
Cash flow per share (Unadj.) Rs49.7417.7-  
Dividends per share (Unadj.) Rs8.500-  
Avg Dividend yield %0.80-  
Book value per share (Unadj.) Rs289.216,349.0-  
Shares outstanding (eoy) m807.15332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.63.4 106.1%   
Avg P/E ratio x29.0-10.6 -274.2%  
P/CF ratio (eoy) x20.532.3 63.5%  
Price / Book Value ratio x3.50.8 426.5%  
Dividend payout %24.20-   
Avg Mkt Cap Rs m822,1644,489,898 18.3%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m38,3010-   
Avg. sales/employee Rs Th078,010.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,127.1-  
INCOME DATA
Net Sales Rs m227,5311,318,372 17.3%  
Other income Rs m5,12125,212 20.3%   
Total revenues Rs m232,6531,343,584 17.3%   
Gross profit Rs m48,07934,548 139.2%  
Depreciation Rs m11,721563,576 2.1%   
Interest Rs m1,09576,078 1.4%   
Profit before tax Rs m40,384-579,893 -7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,896 0.0%   
Tax Rs m12,029-7,349 -163.7%   
Profit after tax Rs m28,355-424,648 -6.7%  
Gross profit margin %21.12.6 806.4%  
Effective tax rate %29.81.3 2,350.4%   
Net profit margin %12.5-32.2 -38.7%  
BALANCE SHEET DATA
Current assets Rs m168,051540,727 31.1%   
Current liabilities Rs m50,333478,345 10.5%   
Net working cap to sales %51.74.7 1,093.4%  
Current ratio x3.31.1 295.4%  
Inventory Days Days7320 374.2%  
Debtors Days Days766 9.8%  
Net fixed assets Rs m117,318149,232 78.6%   
Share capital Rs m1,6140-   
"Free" reserves Rs m231,8450-   
Net worth Rs m233,4605,437,670 4.3%   
Long term debt Rs m01,914,801 0.0%   
Total assets Rs m290,0678,500,316 3.4%  
Interest coverage x37.9-6.6 -571.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.80.2 505.8%   
Return on assets %10.2-4.1 -247.6%  
Return on equity %12.1-7.8 -155.5%  
Return on capital %17.8-4.8 -367.0%  
Exports to sales %22.60-   
Imports to sales %8.90-   
Net fx Rs m44,0800-   
CASH FLOW
From Operations Rs m32,377471,005 6.9%  
From Investments Rs m-23,885258,756 -9.2%  
From Financial Activity Rs m-9,583-808,385 1.2%  
Net Cashflow Rs m-968-78,232 1.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: SHELTER PHARMA  NATURAL CAPS  INNOVA CAPTAB LTD.  STRIDES PHARMA SCIENCE  TORRENT PHARMA  



Today's Market

Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red(10:30 am)

Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.